105 / 1631
Nivolumab in Patients With Relapsed or Refractory Hematologic
Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin A et al J Clin Oncol. 2016 Aug 10;34(23):2698-704.
DLBCL
•
N=11; ORR 36% (n=4), 2 CR, and 2 PR.
•
Median follow-up duration of 22.7 weeks, response durations were 6 and
77.3+ weeks for CR patients and 12.1+ and 22.1 weeks for PR patents.
FL
•
ORR 40% (n=4), including 1 CR and 3 PR.
•
Median follow-up duration of 91.4 weeks, individual response durations
were 81.6+ weeks for the patient with CR and 27.1+, 28.1+, and 32.1+
weeks for the patients with PR.